X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (434) 434
humans (423) 423
male (196) 196
female (189) 189
abridged index medicus (171) 171
cardiac & cardiovascular systems (161) 161
aged (152) 152
peripheral vascular disease (147) 147
stroke (143) 143
warfarin (128) 128
risk factors (127) 127
anticoagulants (122) 122
middle aged (118) 118
aspirin (113) 113
anticoagulants - therapeutic use (111) 111
medicine, general & internal (110) 110
atrial fibrillation (104) 104
hematology (100) 100
treatment outcome (99) 99
prevention (95) 95
drug therapy (88) 88
hemorrhage - chemically induced (83) 83
stroke - prevention & control (83) 83
risk (79) 79
mortality (75) 75
atrial fibrillation - drug therapy (72) 72
anticoagulants - adverse effects (71) 71
thrombosis (65) 65
dabigatran (64) 64
aged, 80 and over (60) 60
care and treatment (60) 60
platelet aggregation inhibitors - therapeutic use (60) 60
thromboembolism (60) 60
anticoagulants - administration & dosage (59) 59
randomized controlled trials as topic (59) 59
health aspects (56) 56
acute coronary syndromes (55) 55
aspirin - therapeutic use (55) 55
metaanalysis (55) 55
hemorrhage (54) 54
warfarin - therapeutic use (52) 52
atrial fibrillation - complications (50) 50
bleeding (50) 50
clopidogrel (50) 50
time factors (49) 49
clinical trials (48) 48
research (48) 48
surgery (48) 48
therapy (48) 48
clinical neurology (47) 47
rivaroxaban (47) 47
atrial-fibrillation (46) 46
dosage and administration (45) 45
heart attacks (44) 44
risk assessment (43) 43
dabigatran etexilate (42) 42
management (42) 42
analysis (41) 41
cardiovascular (41) 41
cardiovascular diseases (41) 41
double-blind method (41) 41
adult (39) 39
cardiovascular disease (39) 39
venous thromboembolism (38) 38
anticoagulation (37) 37
double-blind (37) 37
myocardial-infarction (37) 37
stroke - etiology (37) 37
ticlopidine - analogs & derivatives (37) 37
usage (37) 37
follow-up studies (36) 36
myocardial infarction (36) 36
patients (36) 36
platelet aggregation inhibitors - adverse effects (36) 36
medical and health sciences (35) 35
medicin och hälsovetenskap (35) 35
prospective studies (35) 35
cardiology (34) 34
administration, oral (33) 33
antithrombotic therapy (33) 33
cardiac arrhythmia (33) 33
drug therapy, combination (33) 33
fibrinolytic agents - therapeutic use (33) 33
trial (32) 32
internal medicine (31) 31
stroke - epidemiology (31) 31
stroke prevention (30) 30
antiplatelet therapy (29) 29
apixaban (29) 29
aspirin - adverse effects (29) 29
warfarin - adverse effects (29) 29
incidence (28) 28
molecular-weight heparin (28) 28
myocardial infarction - drug therapy (27) 27
medical research (26) 26
clinical medicine (25) 25
medicine & public health (25) 25
patient outcomes (25) 25
prognosis (25) 25
ticlopidine - therapeutic use (25) 25
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation, ISSN 0009-7322, 09/2014, Volume 130, Issue 13, pp. 1062 - 1071
Journal Article
Anesthesiology, ISSN 0003-3022, 08/2017, Volume 127, Issue 2, pp. 401 - 402
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 02/2014, Volume 63, Issue 4, pp. 321 - 328
Journal Article
European Heart Journal, ISSN 0195-668X, 05/2019, Volume 40, Issue 19, pp. 1528 - 1530
Journal Article
Anesthesiology, ISSN 0003-3022, 08/2017, Volume 127, Issue 2, pp. 401 - 402
Journal Article
Circulation, ISSN 0009-7322, 05/2011, Volume 123, Issue 21, pp. 2363 - 2372
Journal Article
Circulation, ISSN 0009-7322, 03/2014, Volume 129, Issue 9, pp. 961 - 970
BACKGROUND—Renal impairment increases the risk of stroke and bleeding in patients with atrial fibrillation. In the Randomized Evaluation of Long-Term... 
atrial fibrillation | renal insufficiency | anticoagulants | dabigatran | stroke | hemorrhage | warfarin | CARDIAC & CARDIOVASCULAR SYSTEMS | RISK-FACTORS | MANAGEMENT | PREVENTION | APIXABAN | IMPAIRMENT | GLOMERULAR-FILTRATION-RATE | PERIPHERAL VASCULAR DISEASE | EQUATION | SYSTEMIC EMBOLISM | Kidney - physiology | Humans | Middle Aged | Warfarin - adverse effects | Male | Dabigatran | Atrial Fibrillation - physiopathology | Glomerular Filtration Rate - physiology | Warfarin - pharmacology | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Glomerular Filtration Rate - drug effects | beta-Alanine - pharmacology | Aged, 80 and over | Female | Stroke - epidemiology | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Embolism - epidemiology | Benzimidazoles - therapeutic use | beta-Alanine - adverse effects | Kidney - drug effects | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Internationality | Models, Biological | Anticoagulants - pharmacology | Benzimidazoles - pharmacology | Aged | Complications and side effects | Usage | Care and treatment | Warfarin | Atrial fibrillation | Dabigatran etexilate | Kidney diseases | Comparative analysis | Risk factors | Index Medicus | Abridged Index Medicus | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2019, Volume 73, Issue 21, pp. 2769 - 2772
The data and safety monitoring board (DSMB) of a clinical trial is responsible to: 1) protect the interests of the trial participants by monitoring for adverse... 
cardiovascular events | clinical trial stopping guidelines | clinical trials | major bleeding | data monitoring | Cardiac arrhythmia | Anticoagulants | Stroke | Aspirin | Warfarin | Effectiveness | Hemorrhage | Patients | Bleeding | Embolism | Regulatory approval | Antagonism | Fibrillation | Safety | Acute coronary syndromes | Cardiovascular diseases | Monitoring | Vitamin K
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 07/2018, Volume 72, Issue 1, pp. 27 - 28
In the pivotal phase III RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial, which involved 18,113 patients with atrial fibrillation... 
dabigatran | rivaroxaban | apixaban | direct oral anticoagulant | vitamin K antagonist | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | EVENTS | EFFICACY | SAFETY | RISK | ATRIAL-FIBRILLATION | WARFARIN | Myocardial infarction | Anticoagulants | Stroke | Mortality | Cardiovascular disease | Infarction | Health risk assessment
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 2015, Volume 113, Issue 3, pp. 625 - 632
In patients with atrial fibrillation (AF) who require interruption of dabigatran or warfarin for an elective surgery/procedure, the risks and benefits of... 
Warfarin | Dabigatran | Bridging anticoagulation | Surgery | PREDICTING STROKE | MANAGEMENT | ORAL ANTICOAGULATION | RISK | CLASSIFICATION | OPEN-LABEL | I TREAT | warfarin | ATRIAL-FIBRILLATION | THERAPY | ETEXILATE | dabigatran | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | surgery | Perioperative Care | Multivariate Analysis | Dabigatran - adverse effects | Dabigatran - administration & dosage | Anticoagulants - administration & dosage | Postoperative Hemorrhage - prevention & control | Humans | Middle Aged | Warfarin - adverse effects | Male | Warfarin - administration & dosage | Time Factors | Adult | Female | Retrospective Studies | Atrial Fibrillation - diagnosis | Odds Ratio | Surgical Procedures, Operative - adverse effects | Blood Loss, Surgical - prevention & control | Stroke - prevention & control | Drug Administration Schedule | Risk Assessment | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | Proportional Hazards Models | Logistic Models | Treatment Outcome | Anticoagulants - adverse effects | Randomized Controlled Trials as Topic | Postoperative Hemorrhage - etiology | Propensity Score | Stroke - etiology | Aged | Elective Surgical Procedures | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2015, Volume 65, Issue 23, pp. 2481 - 2493
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 05/2018, Volume 71, Issue 20, pp. 2306 - 2315
Background: Patients with lower extremity peripheral artery disease (PAD) are at increased risk of major adverse cardiovascular events (MACE) and major adverse... 
amputation | peripheral artery disease | antithrombotic therapy | death | major adverse limb events | Mortality | Analysis | Intervention | Anticoagulants | Stroke | Prognosis | Complications | Heart surgery | Angioplasty | Health risks | Risk | Cardiovascular disease | Hospitalization | Patients | Incidence | Vascular diseases | Ischemia | Coronary vessels | Amputation | Cardiovascular diseases
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2007, Volume 50, Issue 18, pp. 1742 - 1751
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2018, Volume 71, Issue 24, pp. 2727 - 2730
Efforts to improve outcomes in patients with mechanical heart valves by reducing the risks of thromboembolic and bleeding complications have focused on the use... 
anticoagulation | mechanical heart valve | warfarin | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | VITAMIN-K ANTAGONISTS | PREVENTION | ASPIRIN | ATRIAL-FIBRILLATION | REPLACEMENT | TRIAL | CLOPIDOGREL | THERAPY | HEART-VALVES | Heart | Anticoagulants | Prostheses | Cardiac arrhythmia | Stroke | Aspirin | Cardiovascular disease | Patients | Thrombosis | Prevention | Aorta | Thromboembolism | Health risk assessment | Cardiology | Aortic valve | Prosthetics
Journal Article
by Anand, Sonia S and Bosch, Jackie and Eikelboom, John W and Connolly, Stuart J and Diaz, Rafael and Widimsky, Peter and Aboyans, Victor and Alings, Marco and Kakkar, Ajay K and Keltai, Katalin and Maggioni, Aldo P and Lewis, Basil S and Störk, Stefan and Zhu, Jun and Lopez-Jaramillo, Patricio and O'Donnell, Martin and Commerford, Patrick J and Vinereanu, Dragos and Pogosova, Nana and Ryden, Lars and Fox, Keith A A and Bhatt, Deepak L and Misselwitz, Frank and Varigos, John D and Vanassche, Thomas and Avezum, Alvaro A and Chen, Edmond and Branch, Kelley and Leong, Darryl P and Bangdiwala, Shrikant I and Hart, Robert G and Yusuf, Salim and SALA, JORGELINA and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and SCHYGIEL, PABLO OMAR and CUNEO, CARLOS and LUQUEZ, HUGO and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and MONTANA, OSCAR and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and GARRIDO, MARCELO and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and DRAN, RICARDO DARIO and CARDONA, MARCELO and GUZMAN, RANDOLPH and GUZMAN, LUIS and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and NANI, SEBASTIAN and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and GONZALEZ COLASO, PATRICIA DEL CARMEN and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and ECTOR, BAVO and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and VRANCKX, PASCAL and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and INDIO DO BRASIL, CLARISSE and